{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T14:55:08Z","timestamp":1779116108260,"version":"3.51.4"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1097\/cco.0b013e3283562036","type":"journal-article","created":{"date-parts":[[2012,7,19]],"date-time":"2012-07-19T13:15:25Z","timestamp":1342703725000},"page":"461-465","source":"Crossref","is-referenced-by-count":8,"title":["Maintenance therapy in diffuse large B-cell lymphoma"],"prefix":"10.1097","volume":"24","author":[{"given":"Anne-Sophie","family":"Michallet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laure","family":"Lebras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertrand","family":"Coiffier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-2-20210128","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"R2-2-20210128","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncol"},{"key":"R3-2-20210128","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","article-title":"Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.","volume":"24","author":"Habermann","year":"2006","journal-title":"J Clin Oncol"},{"key":"R4-2-20210128","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1056\/NEJM198706113162401","article-title":"High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkins lymphoma.","volume":"316","author":"Philip","year":"1987","journal-title":"N Engl J Med"},{"key":"R5-2-20210128","first-page":"3562","article-title":"The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group.","volume":"92","author":"Blay","year":"1998","journal-title":"Blood"},{"key":"R6-2-20210128","first-page":"3687","article-title":"Quality of life-adjusted survival analysis of high-dose therapy with autologous bone marrow transplantation versus sequential chemotherapy for patients with aggressive lymphoma in first complete remission. Groupe dEtude les Lymphomes de lAdulte (GELA).","volume":"95","author":"Mounier","year":"2000","journal-title":"Blood"},{"key":"R7-2-20210128","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J Clin Oncol"},{"key":"R8-2-20210128","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa031770","article-title":"Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support.","volume":"350","author":"Milpied","year":"2004","journal-title":"N Engl J Med"},{"key":"R9-2-20210128","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJM199504203321601","article-title":"Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkins lymphoma.","volume":"332","author":"Verdonck","year":"1995","journal-title":"N Engl J Med"},{"key":"R10-2-20210128","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1200\/JCO.2003.08.054","article-title":"Syngeneic hematopoietic stem-cell transplantation for non-Hodgkins lymphoma: a comparison with allogeneic and autologous transplantation - The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation.","volume":"21","author":"Bierman","year":"2003","journal-title":"J Clin Oncol"},{"key":"R11-2-20210128","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/sj.bmt.1703891","article-title":"An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation.","volume":"31","author":"Peniket","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"R12-2-20210128","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/sj.bmt.1705509","article-title":"Alpha-interferon for relapsed non-Hodgkins lymphoma.","volume":"38","author":"Armitage","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"R13-2-20210128","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"key":"R14-2-20210128","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1034\/j.1600-0609.2001.00272.x","article-title":"Interferon alfa 2b as maintenance therapy in poor risk diffuse large B-cell lymphoma in complete remission after intensive CHOP-BLEO regimens.","volume":"66","author":"Aviles","year":"2001","journal-title":"Eur J Haematol"},{"key":"R15-2-20210128","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00432-011-1074-1","article-title":"How to determine post-RCHOP therapy for risk-tailored adult patients with diffuse large B-cell lymphoma, addition of maintenance rituximab or observation: multicenter experience.","volume":"138","author":"Huang","year":"2011","journal-title":"J Cancer Res Clin Oncol"},{"key":"R16-2-20210128","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3816\/CLML.2010.n.004","article-title":"Brief-duration rituximabchemotherapy followed by maintenance rituximab in patients with diffuse large B-cell lymphoma who are poor candidates for R-CHOP chemotherapy: a phase II trial of the Sarah Cannon Oncology Research Consortium.","volume":"10","author":"Hainsworth","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R17-2-20210128","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/nrc1323","article-title":"The evolution of thalidomide and its IMiD derivatives as anticancer agents.","volume":"4","author":"Bartlett","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"R18-2-20210128","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1182\/blood-2005-10-4184","article-title":"Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications.","volume":"108","author":"Chang","year":"2006","journal-title":"Blood"},{"key":"R19-2-20210128","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.leukres.2006.01.010","article-title":"Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly.","volume":"30","author":"Gandhi","year":"2006","journal-title":"Leuk Res"},{"key":"R20-2-20210128","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1158\/0008-5472.CAN-06-2317","article-title":"Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34 progenitor cells.","volume":"67","author":"Verhelle","year":"2007","journal-title":"Cancer Res"},{"key":"R21-2-20210128","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1517\/14656560802627903","article-title":"Lenalidomide: a novel anticancer drug with multiple modalities.","volume":"10","author":"Galustian","year":"2009","journal-title":"Expert Opin Pharmacother"},{"key":"R22-2-20210128","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/sj.leu.2402745","article-title":"Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo.","volume":"17","author":"Lentzsch","year":"2003","journal-title":"Leukemia"},{"key":"R23-2-20210128","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-2141.2007.06841.x","article-title":"Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the antitumour activity of rituximab in vivo.","volume":"140","author":"Reddy","year":"2008","journal-title":"Br J Haematol"},{"key":"R24-2-20210128","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1200\/JCO.2007.15.3429","article-title":"Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkins lymphoma.","volume":"26","author":"Wiernik","year":"2008","journal-title":"J Clin Oncol"},{"key":"R25-2-20210128","doi-asserted-by":"crossref","first-page":"5404","DOI":"10.1200\/JCO.2008.21.1169","article-title":"Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkins Lymphoma.","volume":"27","author":"Witzig","year":"2009","journal-title":"J Clin Oncol"},{"key":"R26-2-20210128","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1200\/JCO.2010.29.8216","article-title":"Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial.","volume":"28","author":"Palumbo","year":"2010","journal-title":"J Clin Oncol"},{"key":"R28-2-20210128","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.3109\/10428194.2011.566951","article-title":"Quality of life in 269 patients with poor-risk diffuse large B-cell lymphoma treated with rituximab versus observation after autologous stem cell transplant.","volume":"52","author":"Heutte","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"R29-2-20210128","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1093\/annonc\/mdp237","article-title":"Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma.","volume":"20","author":"Haioun","year":"2009","journal-title":"Ann Oncol"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCO.0b013e3283562036","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,27]],"date-time":"2024-04-27T08:03:16Z","timestamp":1714204996000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001622-201209000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/cco.0b013e3283562036","relation":{},"ISSN":["1040-8746"],"issn-type":[{"value":"1040-8746","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}